94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1501525
Characteristics, Clinical Evidence and Implementation Effects of Conditional Approvals for Drugs in China, a Pooled Analysis from 2020 to 2023
Provisionally accepted- School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
In late 2019, the conditional approval process for drugs in China transitioned from a pilot project to a formal program. Our study comprehensively analyzed 103 conditional approvals (CAs) authorized by the National Medical Products Administration (NMPA) from 2020 to 2023, specifically focusing on their characteristics, clinical evidence, and implementation effects. It also explored the challenges faced by the CA program in China. The primary findings indicated that nearly 90% of China's CAs were granted for antineoplastics agents, and there were no reported cases of CAs withdrawn by NMPA from the market. Notably, a substantial disparity existed in the pivotal premarketing and completed/ongoing postmarketing clinical trial features and endpoints. Additionally, CAs which initiated confirmation clinical trials before the CA application submission were more likely to obtain regular approval. The efficacy evidence of CAs supported by single-arm trials demonstrated statistically significant variances in indication and drug types. However, no statistical distinctions were observed in the efficacy evidence of CAs supported by randomized controlled trials (RCTs). CAs have been shown to decrease the development time, review time, and drug lag period, notably compared to non-CAs, and differences exist in the development time, review time, and drug lag period among CAs. Furthermore, numerous unmet clinical needs and the public health emergency of COVID-19 have been partially addressed through CAs. However, the approval procedures, clinical evidence evaluation systems, pharmacovigilance, and requirements for confirmatory trials within China's CA framework still require further enhancement.
Keywords: Conditional approvals, Characteristics, clinical evidence, Implementation effects, China
Received: 25 Sep 2024; Accepted: 10 Apr 2025.
Copyright: © 2025 Yang, Fan, Zhang, Huang, Tang and Xue. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Li Yang, School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.